Kenvue (NYSE:KVUE) Trading 4.7% Higher – Time to Buy?

Kenvue Inc. (NYSE:KVUE) traded up 4.7% on Friday . The company traded as high as $17.62 and last traded at $17.6650. 14,250,222 shares were traded during trading, a decline of 56% from the average session volume of 32,055,883 shares. The stock had previously closed at $16.88.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Citigroup reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. UBS Group reduced their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Barclays reduced their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.33.

Kenvue Price Performance

The stock has a market capitalization of $34.01 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 1.34 and a beta of 0.54. The stock’s 50 day moving average is $17.37 and its two-hundred day moving average is $17.48. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company posted $0.24 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insiders Place Their Bets

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Institutional Trading of Kenvue

Hedge funds have recently bought and sold shares of the business. Physician Wealth Advisors Inc. raised its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue in the 4th quarter valued at about $26,000. MV Capital Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter worth $28,000. Reflection Asset Management acquired a new stake in shares of Kenvue in the 4th quarter worth $32,000. Finally, SBI Securities Co. Ltd. increased its stake in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after acquiring an additional 1,027 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.